Rick Winningham
Chief Executive Officer
Replay available
Theravance Biopharma, Inc. (TBPH) Q1 2026 Earnings Call
Theravance Biopharma, Inc. (NASDAQ: TBPH) Q1 2026 earnings conference call, held 2025-12-08. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Horacio Kaufmann
Professor of Neurology and Medicine at New York University; Director of the Dysautonomia Center
Áine Miller
Head of Development
Rhonda Farnham
Chief Business Officer
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Theravance Biopharma, Inc..
Replay transcript excerpt
WEBVTT 00:00:00.335 -- 00:00:04.121 Good morning and welcome to the Theravance Biopharma KOL event. 00:00:04.121 -- 00:00:06.885 At this time, all attendees are in a listen-only mode. 00:00:06.885 -- 00:00:10.290 A question and answer session will follow the formal presentations. 00:00:10.290 -- 00:00:14.116 As a reminder, this call is being recorded and a replay will be made available on the 00:00:14.116 -- 00:00:17.020 Theravance website following the conclusion of the event. 00:00:17.020 -- 00:00:20.906 I'd now like to turn the call over to Rick Winningham, Chief Executive Officer at Theravance 00:00:20.906 -- 00:00:24.268 Biopharma. Please go ahead, Rick. 00:00:24.449 -- 00:00:27.661 Good morning, and thank you for joining us. 00:00:27.661 -- 00:00:32.779 We're excited to host this KOL event focused on ampryloxetine, a medicine with an 00:00:32.779 -- 00:00:34.861 orphan drug designation. 00:00:34.861 -- 00:00:40.592 targeted to treat a rare neurologic disease, neurogenic orthostatic hypotension 00:00:40.592 -- 00:00:45.641 in patients with multiple system atrophy. Amproloxine is finishing 00:00:45.641 -- 00:00:50.670 a pivotal phase three study called Cypress, we'll refer to it during the course of the 00:00:50.670 -- 00:00:55.499 call, with data expected in the first quarter of 2026. 00:00:55.499 -- 00:01:00.624 Today's call is to describe the significant unmet need in symptomatic 00:01:00.624 -- 00:01:05.908 neurogenic orthostatic hypotension, or NOH, and again, patients with multiple system 00:01:05.908 -- 00:01:11.273 atrophy, or MSA, and to show why we believe amproloxetine has the potential 00:01:11.273 -- 00:01:16.598 to change the treatment landscape as a once-daily oral medicine with a durable 00:01:16.598 -- 00:01:18.880 treatment effect, 00:01:18.880 ...